Kairos Pharma, Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KAPA research report →
Companykairospharma.com
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
- CEO
- John S. Yu
- IPO
- 2024
- Employees
- 1
- HQ
- Los Angeles, CA, US
Price Chart
Valuation
- Market Cap
- $10.98M
- P/E
- -1.85
- P/S
- 0.00
- P/B
- 2.03
- EV/EBITDA
- -1.30
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -92.26%
- ROIC
- -114.27%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-5,447,000 · -109.26%
- EPS
- $-0.30 · -30.43%
- Op Income
- $-5,572,000
- FCF YoY
- 13.00%
Performance & Tape
- 52W High
- $2.11
- 52W Low
- $0.40
- 50D MA
- $0.58
- 200D MA
- $0.87
- Beta
- 1.51
- Avg Volume
- 527.64K
Get TickerSpark's AI analysis on KAPA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 8, 25 | Bhowmick Neil | other | 171,756 |
| Oct 8, 25 | Bae Hyun W. | other | 19,084 |
| Sep 16, 25 | Bae Hyun W. | other | 10,000 |
| Oct 8, 25 | Murali Ramachandran | other | 152,672 |
| Oct 8, 25 | Keyoung Hansoo Michael | other | 19,084 |
| Sep 16, 25 | Keyoung Hansoo Michael | other | 10,000 |
| Oct 8, 25 | Singhvi Rahul | other | 19,084 |
| Oct 8, 25 | Samuelson Doug | other | 152,672 |
| Oct 8, 25 | Yu John S | other | 190,840 |
| Dec 10, 24 | Singhvi Rahul | other | 0 |
Our KAPA Coverage
We haven't published any research on KAPA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KAPA Report →